Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ACB US Equity

Aurora Cannabis IncHealth Care · Medicinal Chemicals & Botanical Products · CIK 1683541 · FY ends Mar 31
$3.60
-0.08 (-2.17%)
USD · as of 2026-08-17 · marketstack
1 registered study · 0 active

Studies where ACB is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

1 interventional

Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, D. E. Shaw & Co., Inc., Squarepoint Ops LLC, +2 more) · FINRA short interest 6.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Cannabis Oil for Pain EffectivenessNCT03522467Sustained pain responseOpen-label · TreatmentPhase 2Unknown statusDrug: MRCP001Cancer, Chronic Pain40Jun 20202019-09-25

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19